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We examined a 39-year-old female with severe headache and blurred vision. She was on topiramate, 50mg once a day for one
week because of migraine. Periorbital edema, chemosis, myopia, high intraocular pressures, and shallow anterior chambers were
present at the initial examination. Iridocorneal angles were closed, ultrasound showed choroidal eﬀusions. We stopped topiramate
and started antiglaucoma treatment. After one week the intraocular pressure was 10mmHg in both eyes without treatment. A
new ultrasound showed no choroidal eﬀusions. Topiramate has been associated with acute secondary angle closure glaucoma as
an idiosyncratic reaction to the drug. Physicians prescribing topiramate need to alert patients of this potential sight-threatening
idiosyncratic reaction.
1.Introduction
Topiramate, a sulfamate-substituted monosaccharide, is pri-
marily used in the treatment of epilepsy, however, it has also
demonstrated eﬃcacy in the treatment of migraine, depres-
sion, bipolar disorders, neuropathic pain, posttraumatic
stress disorder, postherpetic neuropathy, idiopathic intracra-
nial hypertension, and as “oﬀ-label application” it has been
used for weight loss, adjunctive therapy for alcoholism and
nicotine cessation [1–3]. Topiramate is prescribed for adults
and pediatric patients aged 2 to 16 years with partial-onset
seizures or primary generalized tonic-clonic seizures [4].
It was launched into the market in 1996, and only 5
years later Banta et al. [5] reported the ﬁrst case of acute
angle closure glaucoma (AACG). On September 2001,
Ortho-McNeil Pharmaceuticals inserted an alert in the box
indicating that 23 cases of AACG had been reported to their
safety division, and physician should be aware of this adverse
ocular drug reaction [6].
The ocular adverse reaction consists of peripheral cilio-
choroidaleﬀusionwithciliarybodyedemaandanteriorrota-
tion of the ciliary body. There is an anterior shifting of the
lens iris diaphragm shallowing the anterior chamber in the
periphery causing the AACG without pupillary block. The
exact mechanism of the ciliochoroidal eﬀusion is unknown.
It is believed to be an idiosyncratic adverse reaction to the
drug.
Several drugs have been responsible for sporadic cases of
bilateral acute angle closure glaucoma with choroidal eﬀu-
sions secondary to an idiosyncratic reaction [7].
2.CaseReport
A 39-year-old woman was seen because of headache, blurred
vision, and lid edema for the past 2 days. Her prior refraction
was OD: +1.75sph and OS: +1.25sph, her BCV was 20/20.
At the time of examination, the uncorrected VA was of
20/70 in each eye. A new refraction showed OD: −1.50 =
−0.75 × 100, and OS: −2.00 =− 1.00 × 110. Her IOP was
OD 36mmHg, and OS 40mmHg, anterior chambers were
shallow, pupils were 5mm and slightly reactive to light, and
theopticcup/discratiowas0.3inbotheyes.Theiridocorneal
angle was closed 360 degrees in both eyes.
A B-scan was performed. 360 degrees choroidal detach-
ment was identiﬁed. In the longitudinal cut the choroidal
detachment was in the periphery near the ciliary body.2 Case Reports in Ophthalmological Medicine
Immersionscanshowedthattheanteriorchamberdepthwas
0.9mm for the OD, and 1.1mm for the OS. The axial length
of both eyes was 21.8mm (Figure 1).
She had been taking topiramate 50mg a day for migraine
7 days before she started with the symptoms. With the
approval of her neurologist, topiramate was discontinued.
Travaprost 0.005% once a day, Timolol 0.5% BID, and
oral acetazolamide 250mg orally QID were prescribed. Next
day uncorrected VA was 20/40 in each eye, her IOP was
10mmHg in each eye, and oral acetazolamide was discon-
tinued.Oneweekafterthecessationoftopiramateher,BCVA
was 20/20 with her past hypermetropic refraction, the IOP
was 10mmHg in each eye, she had no angle synecquias,
the anterior chamber was deep, and the optic nerve and the
retina were normal.
The anterior chamber depth was 3.05mm on the right
eye and 2.95mm on the left eye with the A-scan. B-scan
showed no ciliochoroidal eﬀusions. Antiglaucoma treatment
was discontinued 7 days after the cessation of topiramate.
3. Discussion
We cannot predict an idiosyncratic reaction, but we must
be aware of the consequences. Acute angle closure glaucoma
is an ophthalmological emergency. Prompt diagnosis and
treatment is crucial to maintain healthy eyes after high
intraocular pressure has been recognized.
Some important facts about this entity are idiosyncratic
reactiontotopiramatecanhappenatanyage,themechanism
is caused by choroidal eﬀusions in contrast to the usual
age range, and mechanisms of angle closure glaucoma. The
widespread use of topiramate will probably represent an
increase in frequency of acute angle closure glaucoma cases,
and it is already showing in the literature as case reports
[8, 10, 12]. Treatment consists in stopping topiramate and
lower the intraocular pressure. Miotics and iridotomies are
of no use in this entity. Physicians prescribing topiramate
need to be aware of this idiosyncratic reaction for the ﬁrst
2 weeks or if an increase in the dose is needed. Suspect
this entity when there is a myopic shift and acute angle
closure glaucoma in a patient on topiramate. Usually around
2 weeks after starting the medication as shown on Table 1.
The diagnosis is conﬁrmed by ultrasound with the presence
of peripheral choroidal eﬀusion. First step in treatment
is to stop topiramate. Topical and systemic antiglaucoma
medicationsareprescribedtolowertheIOP.Cycloplegicscan
help deepening the anterior chamber. Some authors suggest
using systemic steroids with the rationale that the ciliary
body edema could be caused by inﬂammation [11].
There is a report of a case with lens-corneal touch that
did not improve with topical and systemic treatment, they
did a choroidal drainage with resolution of the AACG. In
this case the patient was treated initially with pilocarpine
that worsened the clinical picture. Miotics are not helpful in
this entity [9]. Iridotomies are not useful because there is no
pupillary block. Ecography helps us to rule out intraocular
tumors or bilateral iris cyst in the periphery that could also
p r o d u c eab i l a t e r a lA A C G .
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Figure 1: B-scan showing peripheral choroidal eﬀusion (arrow).
Table 1
Author Year Time taking topiramate
Banta et al. [5] April 99–July 2001 4 to 21 days (mean 10 days)
Medeiros
et al. [8] 2003 5 days and 10 days
Lin et al. [4] 2004 10 days
Parikh et al. [9] 2007 2 weeks
Sbeity et al. [10] 2009 2 weeks
Willett and
Edward [11] 2011 10 days
4. Conclusion
Most reports indicate regression of symptoms and signs
whenstoppingtakingtopiramate.However,ifnotrecognized
as a drug related event, permanent visual loss can occur. It is
important to alert physicians and patients using Topiramate
forearlyrecognitionofsignsandsymptomsofthisentityand
prevent permanent damage.
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